白血病儿童化疗后继发侵袭性真菌病的现状及博纳吐单抗桥接治疗的研究进展  

Current situation of invasive fungal disease secondary to chemotherapy in leukemia children and progress of blinatumomab as a bridging therapy

作　　者：潘冬杰 曹玲 Pan Dongjie;Cao Ling(Department of Respiratory Medicine,Capital Institute of Pediatrics-Peking University Teaching Hospital,Children's Hospital Capital Institute of Pediatrics,Beijing 100020,China)

机构地区：[1]北京大学首都儿科研究所教学医院、首都儿科研究所附属儿童医院呼吸内科,100020

出　　处：《国际儿科学杂志》2024年第9期582-585,共4页International Journal of Pediatrics

摘　　要：白血病患儿在化疗后常面临严重的骨髓抑制,导致其继发侵袭性真菌病(invasive fungal disease,IFD)的概几率大幅提高,这不仅增加了治疗的复杂性,也使患儿病死率上升。为了促进免疫功能恢复,在抗感染治疗过程中通常会暂时中断化疗,但这可能导致白血病复发。博纳吐单抗作为一种双特异性T细胞衔接剂,在合并IFD的白血病桥接治疗中具有一定的优势。该文对白血病患儿化疗后继发IFD的现状以及博纳吐单抗作为桥接治疗药物的相关研究进行了梳理总结,为其治疗提供更多思路。Children with leukemia always experience severe bone marrow suppression following chemotherapy,significantly increasing their susceptibility to invasive fungal disease(IFD),which not only complicates treatment but also leads to higher fatality rates.Temporary interruption of chemotherapy during anti-infection treatment is suggested in order to restore immune function,but this may also results in leukemia relapse.Blinatumomab,a bispecific T-cell engager,has demonstrated benefits as a bridging therapy for children with leukemia and IFD.This article provides a comprehensive overview of the current landscape of IFD secondary to chemotherapy in leukemia children and the relevant researches on blinatumomab as a bridging therapeutic agent,so as to provide more ideas for its treatment.

关 键 词：儿童 白血病 博纳吐单抗 侵袭性真菌病 

分 类 号：R733.7[医药卫生—肿瘤]